Cardinal Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$CAH
Other Pharmaceuticals
Health Care
Get the next $CAH alert in real time by email
cah-20240423
0000721371false00007213712024-04-232024-04-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 23, 2024
Cardinal Health, Inc.
(Exact name of registrant as specified in its charter)
Ohio1-1137331-0958666
(State or other
jurisdiction of incorporation)
(Commission
File Number)

(IRS Employer
Identification No.)
7000 Cardinal Place, Dublin, Ohio 43017
(614) 757-5000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common shares (without par value)CAHNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   p









Item 7.01. Regulation FD Disclosure
As previously announced, beginning in the third quarter of fiscal year 2024, Cardinal Health, Inc. (the “Company”) updated its organizational structure and re-aligned its operating and reporting segments to continue the company’s simplification efforts, prioritize core operational execution and drive efficiency, accountability and transparency. In connection with these efforts, the Company is now voluntarily furnishing unaudited recast segment results under its new structure for each quarter of fiscal years 2022 and 2023 and the first two quarters of fiscal year 2024. These results are attached hereto as Exhibit 99.1 and incorporated herein by reference.

The new reporting segments are the Pharmaceutical and Specialty Solutions segment and the Global Medical Products and Distribution segment. Separate from these segments are three operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics, which are not significant enough individually to require reportable segment disclosure. These operating segments are reported as Other.

These unaudited recast segment results do not represent a restatement of previously issued financial statements and do not impact the company’s reported consolidated revenue, operating earnings/(loss), net earnings/(loss) or diluted earnings/(loss) per share for any of the previously reported periods. The recast segment results reflect changes in the elimination of inter-segment revenue and allocated corporate expenses for shared functions, which are driven by the reporting structure change. The company will prepare financial results on the basis of its updated structure beginning in the third quarter of fiscal year 2024.
.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.





Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Cardinal Health, Inc.
(Registrant)
Date:April 23, 2024By:/s/ AARON E. ALT
Aaron E. Alt
Chief Financial Officer


Get the next $CAH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CAH

DatePrice TargetRatingAnalyst
1/8/2025$130.00 → $144.00Hold → Buy
TD Cowen
1/7/2025$140.00In-line → Outperform
Evercore ISI
1/6/2025$132.00 → $145.00Neutral → Buy
BofA Securities
12/13/2024$101.00 → $127.00Underweight → Equal Weight
Wells Fargo
12/4/2024$139.00Outperform
Mizuho
2/26/2024$125.00Outperform
Leerink Partners
2/9/2024Hold → Buy
Argus
1/3/2024$117.00Overweight
Barclays
More analyst ratings

$CAH
Press Releases

Fastest customizable press release news feed in the world

See more
  • Cardinal Health to open new distribution center in Fort Worth, Texas

    New facility will be outfitted with latest robotics and automation technologies DUBLIN, Ohio, Jan. 14, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced construction is underway on a new distribution center in Fort Worth, Texas, which will support its at-Home Solutions business, a leading medical supplies provider that serves more than 5 million patients annually in the United States. The new 340,000 square foot distribution center will consolidate its two existing warehouses into one larger facility, creating approximately 74,000 additional square feet of inventory ca

    $CAH
    Other Pharmaceuticals
    Health Care
  • RPM Announces Appointment of Three New Board Members

    RPM International Inc. (NYSE:RPM) today announced the appointment of three individuals, Craig S. Morford, Christopher L. Mapes and Julie A. Beck, to its board of directors. These appointments reflect RPM's ongoing commitment to expanding the expertise, diversity and leadership capabilities of its board as the company continues to drive long-term growth and shareholder value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113146614/en/Christopher L. Mapes (Photo: Business Wire) The appointments of Mr. Morford and Mr. Mapes are effective immediately, and Ms. Beck's term is set to commence on April 7, 2025. With these additions,

    $AOS
    $CAH
    $LECO
    $NDSN
    Consumer Electronics/Appliances
    Consumer Discretionary
    Other Pharmaceuticals
    Health Care
  • Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2025 on January 30

    DUBLIN, Ohio, Dec. 19, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2025 on January 30, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern. To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months. About Cardinal Health Cardin

    $CAH
    Other Pharmaceuticals
    Health Care

$CAH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CAH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CAH
SEC Filings

See more

$CAH
Leadership Updates

Live Leadership Updates

See more
  • RPM Announces Appointment of Three New Board Members

    RPM International Inc. (NYSE:RPM) today announced the appointment of three individuals, Craig S. Morford, Christopher L. Mapes and Julie A. Beck, to its board of directors. These appointments reflect RPM's ongoing commitment to expanding the expertise, diversity and leadership capabilities of its board as the company continues to drive long-term growth and shareholder value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113146614/en/Christopher L. Mapes (Photo: Business Wire) The appointments of Mr. Morford and Mr. Mapes are effective immediately, and Ms. Beck's term is set to commence on April 7, 2025. With these additions,

    $AOS
    $CAH
    $LECO
    $NDSN
    Consumer Electronics/Appliances
    Consumer Discretionary
    Other Pharmaceuticals
    Health Care
  • Bob Azelby to join Cardinal Health Board of Directors

    DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1. Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries. Mr. Azelby has previously served as President and Chief Executive Officer of Eliem Therapeutics, and prior to Eliem, he was the Chief Executive Officer of Alder BioPharmac

    $CAH
    Other Pharmaceuticals
    Health Care
  • Cardinal Health Reports First Quarter Fiscal 2023 Results

    Revenue increased 13% to $49.6 billionGAAP1 operating earnings were $137 million, GAAP diluted EPS were $0.40Non-GAAP operating earnings decreased 20% to $423 million due to a decline in Medical segment profit, partially offset by an increase in Pharmaceutical segment profit; non-GAAP diluted EPS decreased 7% to $1.20Company reaffirmed fiscal year 2023 non-GAAP EPS guidanceDUBLIN, Ohio, Nov. 4, 2022 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported first quarter fiscal year 2023 revenues of $49.6 billion, an increase of 13% from the first quarter of last year. First quarter GAAP operating earnings were $137 million, including a non-cash, pre-tax goodwill impairment charge of $154 mil

    $CAH
    Other Pharmaceuticals
    Health Care

$CAH
Financials

Live finance-specific insights

See more
  • Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Nov. 5, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on January 15, 2025 to shareholders of record at the close of business on January 2, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuc

    $CAH
    Other Pharmaceuticals
    Health Care
  • Cardinal Health Reports First Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook

    Revenue decreased 4% to $52.3 billion; revenue increased 15% excluding the impact of the previously communicated large customer contract expirationGAAP1 operating earnings were $568 million; GAAP diluted EPS was $1.70Non-GAAP operating earnings increased 12% to $625 million, driven by significant growth in Pharmaceutical and Specialty Solutions segment profitNon-GAAP diluted EPS increased 9% to $1.88Fiscal year 2025 non-GAAP EPS guidance2 raised to $7.75 to $7.90, from $7.55 to $7.70DUBLIN, Ohio, Nov. 1, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2025 revenue of $52.3 billion, a decrease of 4% from the first quarter of fiscal year 2024. First qu

    $CAH
    Other Pharmaceuticals
    Health Care
  • Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Aug. 15, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on October 15, 2024 to shareholders of record at the close of business on October 1, 2024. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business

    $CAH
    Other Pharmaceuticals
    Health Care

$CAH
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more